Pharmacokinetic and pharmacological features of oestradiol valerate

Add time:07/28/2019    Source:sciencedirect.com

Natural oestrogenic hormones are the appropriate substances for the therapy of climacteric complaints. After oral or parenteral administration, oestradiol valerate, the synthesis compound contained in various commercially available preparations, is completely converted into the natural substances 17β-oestradiol and valeric acid. The 17β-oestradiol produced on cleavage of the ester behaves in the organism like the endogenous steroid hormone. Oestradiol valerate and 17β-oestradiol are virtually dose-equivalent. No differences in the spectrum of action of the oestrogen and its ester have been found either in animal experiments or man. The pharmacokinetic behaviour and the biotransformation of the 17β-oestradiol originating from oestradiol valerate are no different from those of natural 17β-oestradiol. Differences of practical significance exist in respect of the quantitative effect of oestradiol valerate following oral and intramuscular administration, whereas 4 mg oestradiol valerate administered intramuscularly is therapeutically sufficient for a period of 2–4 wk (depot effect). As much as 2 mg daily over 3 wk must be administered via the oral route to achieve the same effect. This difference is due to the greatly diverging pharmacokinetic behaviour of oestradiol valerate depending on which of the two modes of administration is employed.

We also recommend Trading Suppliers and Manufacturers of BENZYL VALERATE (cas 10361-39-4). Pls Click Website Link as below: cas 10361-39-4 suppliers

Prev:Removal of high concentration of sulfate from pigment industry effluent by chemical precipitation using Barium chloride (cas 10361-37-2): RSM and ANN modeling approach
Next:Soluble phenyl valerate esterases of hen sciatic nerve and the potentiation of organophosphate induced delayed polyneuropathy)